Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE

Rheumatology (United Kingdom)

Volumn 56, Issue 10, 2017, Pages 1746-1754

  Morel, Jacques ^a   Constantin, Arnaud ^b   Baron, Gabriel ^c   Dernis, Emmanuelle ^d   Flipo, René Marc ^e   Rist, Stéphanie ^f   Combe, Bernard ^a   Gottenberg, Jacques Eric ^g   Schaeverbeke, Thierry ^h   Soubrier, Martin ⁱ   Vittecoq, Olivier ^j   Dougados, Maxime ^k   Saraux, Alain ^l   Mariette, Xavier ^m   Ravaud, Philippe ^c   Sibilia, Jean ^g  

^a UNIV MONTPELLIER   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c PARIS DESCARTES UNIVERSITY   (France)

^d General Hospital of le Mans   (France)

^e UNIV LILLE   (France)

^f Pediatric Endocrinology Unit   (France)

^g UNIVERSITÉ DE STRASBOURG   (France)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ UNIVERSITÉ CLERMONT AUVERGNE   (France)

^j UNIVERSITÉ DE ROUEN   (France)

^k University of Paris Descartes ^*  (France)

^l UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^m INSERM U1184   (France)

more..

Author keywords

DMARDs; Observational study; Registry; Rheumatoid arthritis; Risk factors; Safety; Serious infection; Steroids; Tocilizumab; Tolerance

Indexed keywords

ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; PENICILLIN DERIVATIVE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INCIDENCE; INFECTION; INFECTION RISK; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEUTROPHIL COUNT; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN INFECTION; SOFT TISSUE INFECTION; UROGENITAL TRACT INFECTION; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; EVALUATION STUDY; FRANCE; IMMUNOLOGY; LEUKOCYTE COUNT; NEUTROPHIL; OPPORTUNISTIC INFECTIONS; PROPORTIONAL HAZARDS MODEL; REGISTER;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HUMANS; INCIDENCE; ISOXAZOLES; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; OPPORTUNISTIC INFECTIONS; PEPTIDES, CYCLIC; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS;

EID: 85030770022     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex238     Document Type: Article

References (20)

1. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
2. Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32
3. Salmon JH, Gottenberg JE, Ravaud P et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis 2016;75:1108-13
4. Dixon WG, Watson K, Lunt M et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
5. Curtis JR, Yang S, Patkar NM et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990-7
6. Singh JA, Cameron C, Noorbaloochi S et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015;386:258-65
7. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev 2010;(7):CD008331
8. Winthrop KL, Novosad SA, Baddley JW et al. Opportunistic infections and biologic therapies in immunemediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74:2107-16
9. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32
10. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70:2148-51
11. Genovese MC, Rubbert-Roth A, Smolen JS et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80
12. Iking-Konert C, von Hinuber U, Richter C et al. ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany. Rheumatology 2016;55:624-35
13. Lang VR, Englbrecht M, Rech J et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology 2012;51:852-7
14. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44
15. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
16. Weaver A, Troum O, Hooper M et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 2013;40:1275-81
17. Emery P, Gallo G, Boyd H et al. Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 2014;32:653-60
18. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2006;20:849-63
19. Willemze A, van der Linden MP, le Cessie S et al. The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. Ann Rheum Dis 2011;70:1697-8
20. Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20